Companies Harpoon Therapeutics, Inc.
Harpoon Therapeutics (HARP): executive pay, fiscal 2022
Free brief. Every figure links to the company’s own filing.
Harpoon Therapeutics, Inc. no longer files a proxy statement; its last pay data is FY2022.
CEO pay, last three years
- $2,227,341FY2021
- $1,160,774FY2022
CEO total pay was $1,160,774 in fiscal 2022, down from $2,227,341 in fiscal 2021.
FY2022: salary $565,000 · bonus $62,150 · stock awards $250,000 · option awards $0
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Holger Wesche | $430,000 | $0 | $0 | $471,135 | $0 | $0 | $531,769 | $1,432,904 |
| Former Chief Science Officer (10) | ||||||||
| Julie Eastland | 565,000 | 62,150 | 250,000 | 0 | 217,525 | 0 | 66,099 | 1,160,774 |
| President, Chief Executive Officer and Director | ||||||||
| Natalie Sacks | 206,625 | 0 | 0 | 540,970 | 0 | 0 | 9,685 | 757,280 |
| Former Chief Medical Officer (9) | ||||||||
| Georgia Erbez | 316,690 | 0 | 0 | 401,294 | 0 | 0 | 9,863 | 727,847 |
| Former Chief Financial Officer (8) | ||||||||
| Luke Walker | 125,000 | 250,000 | 0 | 244,530 | 48,767 | 0 | 667 | 668,964 |
| Chief Medical Officer (7) | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| Holger Wesche | $1,432,904 | $1,845,521 | — | ↓ −412,617 |
| Julie Eastland | 1,160,774 | 2,227,341 | — | ↓ −1,066,567 |
| Natalie Sacks | 757,280 | 2,675,862 | — | ↓ −1,918,582 |
| Georgia Erbez | 727,847 | 2,227,647 | — | ↓ −1,499,800 |
| Luke Walker | 668,964 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2022
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Holger Wesche | Option | 14,169 | 13.29 | — |
| Holger Wesche | Option | 27,084 | 18.66 | — |
| Holger Wesche | Option | 67,500 | 7.73 | — |
| Holger Wesche | Option | 104,063 | 5.03 | — |
| Julie Eastland | Option | 255,209 | 6.85 | — |
| Luke Walker | Option | 305,000 | 1.08 | — |
| Julie Eastland | PSU | 375,000 | — | 272,250 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Scott MyersIndependent · Board Chair · Audit Committee · Nominating and Corporate Governance Committee (Chair) | $80,500 | — | $29,118 | — | — | $109,618 |
| Joanne Viney, Ph.DIndependent · Audit · Research and Development (Chair) · Not standing for re-election | 52,500 | — | 14,559 | — | — | 67,059 |
| Andrew RobbinsIndependent · Audit Committee · Compensation Committee | 47,500 | — | 14,559 | — | — | 62,059 |
| Ronald HuntIndependent · Compensation Committee (Chair) | 45,000 | — | 14,559 | — | — | 59,559 |
| Mark ChinIndependent · Compensation Committee | 45,000 | — | 14,559 | — | — | 59,559 |
| Joseph Bailes, M.DIndependent · Audit · Nominating and Corporate Governance · Research and Development | 44,000 | — | 14,559 | — | — | 58,559 |
| Jonathan Drachman, M.DIndependent · Audit · Nominating and Corporate Governance · Research and Development | 44,000 | — | 14,559 | — | — | 58,559 |
| Alan Colowick, M.DIndependent · Compensation · Not standing for re-election | 40,000 | — | 14,559 | — | — | 54,559 |
| Lauren P. SilvernailIndependent · Audit Committee (Chair) | 14,538 | — | 23,217 | — | — | 37,755 |
Board fee structure and ownership guideline
| Annual cash retainer | $35,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 5,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $413,038 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $413,038 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Harpoon Therapeutics as a peer
Companies that benchmark against HARP
No companies currently name HARP as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Harpoon Therapeutics, Inc. | 2022 | Julie Eastland | $565,000 | $250,000 | $0 | $217,525 | $1,160,774 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | 2 : 1 |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (18 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Holger Wesche. DEF 14A, filed 2023-04-27. Section “Executive Compensation”. As printed: 1,432,904. View filing ↗
- Section 01, Julie Eastland. DEF 14A, filed 2023-04-27. Section “Executive Compensation”. As printed: 1,160,774. View filing ↗
- Section 01, Natalie Sacks. DEF 14A, filed 2023-04-27. Section “Executive Compensation”. As printed: 757,280. View filing ↗
- Section 01, Georgia Erbez. DEF 14A, filed 2023-04-27. Section “Executive Compensation”. As printed: 727,847. View filing ↗
- Section 01, Luke Walker. DEF 14A, filed 2023-04-27. Section “Executive Compensation”. As printed: 668,964. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2023-04-27. Section “CEO Pay Ratio”. As printed: 2 : 1. View filing ↗
- Section 08, Scott Myers. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 109,618. View filing ↗
- Section 08, Joanne Viney, Ph.D. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 67,059. View filing ↗
- Section 08, Andrew Robbins. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 62,059. View filing ↗
- Section 08, Ronald Hunt. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 59,559. View filing ↗
- Section 08, Mark Chin. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 59,559. View filing ↗
- Section 08, Joseph Bailes, M.D. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 58,559. View filing ↗
- Section 08, Jonathan Drachman, M.D. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 58,559. View filing ↗
- Section 08, Alan Colowick, M.D. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 54,559. View filing ↗
- Section 08, Lauren P. Silvernail. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 37,755. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 413,038 + equity 0 + all other 0 = 413,038, summed across the director compensation table rows.
- Harpoon Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2023-04-27. CEO total compensation as printed in Harpoon Therapeutics, Inc.'s own proxy. As printed: 1,160,774. View filing ↗